Aktie A206640 BODITECH MED INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Boditech Med Inc.

Aktien

A206640

KR7206640005

A206640

Schlusskurs Korea S.E.
Andere Börsenplätze
 00:00:00 17.05.2024 		% 5 Tage % 1. Jan.
17.370 KRW +0,35 % Intraday Chart für Boditech Med Inc. +7,16 % -15,27 %
2023 Boditech Med Inc. und SphingoTec GmbH schließen eine Marktentwicklungsvereinbarung, um die Kommerzialisierung des Nierenfunktions-Biomarkers PenKid voranzutreiben CI
2022 Boditech Med Inc. und SphingoTec GmbH schließen einen nicht-exklusiven, lizenzpflichtigen Lizenzvertrag ab CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
4TEEN4 Pharmaceuticals GmbH announced that it has received funding from Boditech Med Inc.
Boditech Med Inc. and SphingoTec GmbH Enter into Market Development Agreement to Boost Commercialization of Kidney Function Biomarker PenKid
MENARINI ANNOUNCES AN EXCLUSIVE DISTRIBUTION AGREEMENT FOR BODITECH'S AFIAS-10 SYSTEM
Tranche Update on Boditech Med Inc.'s Equity Buyback Plan announced on September 29, 2022.
Tranche Update on Boditech Med Inc.'s Equity Buyback Plan announced on September 29, 2022.
Boditech Med Inc.'s Equity Buyback announced on September 29, 2022, has expired with 496,620 shares, representing 2.21% for KRW 4,994.56 million
Tranche Update on Boditech Med Inc.'s Equity Buyback Plan announced on September 29, 2022.
Boditech Med Inc. and SphingoTec GmbH Enters into Non-Exclusive Royalty-Bearing License Agreement
Boditech Med Inc. announces an Equity Buyback for KRW 5,000 million worth of its shares.
Boditech Med Inc. authorizes a Buyback Plan.
Tranche Update on Boditech Med Inc.'s Equity Buyback Plan announced on December 14, 2021.
Boditech Med Inc.'s Equity Buyback announced on December 14, 2021, has expired with 297,901 shares, representing 1.31% for KRW 4,987.06 million.
Novo Integrated Sciences, Boditech Med Sign Memorandum of Understanding for Distribution of Diagnostic Technologies
Novo Integrated Sciences, Inc. Signs Memorandum of Understanding with Boditech Med to Market and Distribute in North America
Boditech Med Announces the Formation of a U.S. Based Advisory Board and its First Member, Zachariah P. Zachariah, M.D
Boditech Med Partners with Novo Integrated Sciences, Inc. to Market and Distribute Lower-Cost, Rapid Testing in North America
Boditech Med to Expand to U.S., North America
Tranche Update on Boditech Med Inc.'s Equity Buyback Plan announced on December 14, 2021.
Tranche Update on Boditech Med Inc.'s Equity Buyback Plan announced on September 6, 2021.
Tranche Update on Boditech Med Inc.'s Equity Buyback Plan announced on September 6, 2021.
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A206640 Aktie
  4. Nachrichten Boditech Med Inc.
  5. Andere Sprachen